Skip to main content
×
Home
    • Aa
    • Aa
  • The International Journal of Neuropsychopharmacology, Volume 11, Issue 4
  • June 2008, pp. 445-452

A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder

  • Eduard Vieta (a1), Nuria Cruz (a1), Javier García-Campayo (a2), Rosario de Arce (a3), Jose Manuel Crespo (a4), Vicens Vallès (a5), Josefina Pérez-Blanco (a6), Ernesto Roca (a7), Jose Manuel Olivares (a8), Angel Moríñigo (a9), Raul Fernández-Villamor (a10) and Merce Comes (a1)
  • DOI: http://dx.doi.org/10.1017/S1461145708008596
  • Published online: 01 March 2008
Abstract
Abstract

We evaluated the prophylactic efficacy and the long-term tolerability of oxcarbazepine administration in the treatment of bipolar I and II disorder as an adjunctive therapy to lithium. We conducted a 52-wk, double-blind, randomized, placebo-controlled, parallel-group, multicentre, clinical trial. Bipolar I and II DSM-IV outpatients, having had two or more episodes in the last year, but currently being in remission, were randomly assigned on a 1:1 ratio to oxcarbazepine (n=26) or placebo (n=29) as adjuncts to ongoing treatment with lithium. The primary efficacy variable was the length of the remission period assessed by means of the Young Mania Rating Scale (YMRS) and Montgomery–Asberg Depression Rating Scale (MADRS). Other assessments were the Clinical Global Impression (CGI-BP-M), functional activity (GAF), anxiety (HAMA) and impulsiveness (BIS-11). The average time until first recurrence of any type was 19.2±13.9 wk and 18.6±17.0 wk for oxcarbazepine and placebo respectively (p=0.315). Ten (38.46%) patients had a recurrence of any kind in the oxcarbazepine group vs. 17 (58.62%) in the placebo group (p=0.1354). There was a trend for depressive episodes being less likely in the oxcarbazepine group compared to the placebo group (11.54% and 31.03% respectively, p=0.085), and for better functionality with the GAF (p=0.074). Impulsivity was significantly better prevented by oxcarbazepine (p=0.0443). Overall, oxcarbazepine was well tolerated. This pilot, randomized clinical trial, suggests that oxcarbazepine might have some prophylactic efficacy with regards to impulsivity and perhaps mood episodes in patients taking lithium, although further, adequately powered controlled trials are needed to confirm these findings.

Copyright
Corresponding author
Address for correspondence: Dr E. Vieta, Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Villarroel 170/Rossello 140, Barcelona 08036, Spain. Tel.: 34 932 275 401Fax: 34 932 279 876E-mail: EVIETA@clinic.ub.es
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

A Benedetti , L Lattanzi , S Pini , L Musetti , L Dell'Osso , GB Cassano (2004). Oxcarbazepine as add-on treatment in patients with bipolar, mixed or depressive episode. Journal of Affective Disorders 79, 273277.

JF Cabrera , HD Mühlbauer , J Schley , KD Stoll , B Müller-Oerlinghausen (1986). Long-term randomized clinical trial on oxcarbazepine vs lithium in bipolar and schizoaffective disorders: preliminary results. Pharmacopsychiatry 19, 282283.

F Centorrino , MJ Albert , JM Berry , JP Kelleher , V Fellman , G Line , AE Koukopoulos , JE Kidwell , KV Fogarty , RJ Baldessarini (2003). Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disorder 5, 370374.

F Colom , E Vieta , A Martinez-Aran , M Garcia-Garcia , M Reinares , C Torrent , JM Goikolea , S Banus , M Salamero (2002). Spanish version of a scale for the assessment of mania: validity and reliability of the Young Mania Rating Scale [in Spanish]. Medicina Clinica (Barcelona) 119, 366371.

HM Emrich , H Altmann , M Dose , D Von Zerssen (1983). Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacology Biochemistry and Behavior 19, 369372.

HM Emrich , M Dose , D von Zersson (1985). The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. Journal of Affective Disorders 8, 243250.

KN Fountolakis , E Vieta , J Sanchez-Moreno , SG Kaprinis , JM Goikolea , GS Kaprinis (2005). Treatment guidelines for bipolar disorder: a critical review. Journal of Affective Disorders 86, 110.

SN Ghaemi , DA Berv , J Klugman , KJ Rosenquist , DJ Hsu (2003). Oxcarbazepine treatment of bipolar disorder. Journal of Clinical Psychiatry 64, 4345.

G Goodwin , E Vieta (2005). Effective maintenance treatment-breaking the cycle of bipolar disorder. European Psychiatry 20, 365371.

H Grunze , S Kasper , G Goodwin , C Bowden , D Baldwin , RW Licht , E Vieta , HJ Moller (2003). WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World Journal of Biological Psychiatry 4, 513.

M Hamilton (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 5055.

RM Hirschfeld , S Kasper (2004). A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. International Journal of Neuropsychopharmacology 7, 507522.

SA Montgomery , MA Asberg (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382389.

E Popova , C Leighton , A Benabarre , M Bernardo , E Vieta (2007). Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Review of Neurotherapeutics 7, 617626.

JB Singh , CA Zarate Jr. (2006). Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials. Bipolar Disorder 8, 696709.

T Suppes , EB Dennehy , RM Hirschfeld , LL Altshuler , CL Bowden , JR Calabrese , ML Crismon , TA Ketter , GS Sachs , AC Swann (2005). The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Journal of Clinical Psychiatry 66, 870886.

E Vieta , X Carne (2005). The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychotherapy and Psychosomatics 74, 1016.

E Vieta , C Gastó , A Otero , E Nieto , J Vallejo (1997). Differential features between bipolar I and bipolar II disorder. Comparative Psychiatry 38, 98101.

E Vieta , J Manuel Goikolea , A Martínez-Arán , M Comes , K Verger , X Masramon , J Sanchez-Moreno , F Colom (2006). A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Journal of Clinical Psychiatry 67, 473477.

KD Wagner , RA Kowatch , GJ Emslie , RL Findling , TE Wilens , K McCague , J D'Souza , A Wamil , RB Lehman , D Berv , (2006). A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. American Journal of Psychiatry 163, 11791186.

LN Yatham , SH Kennedy , C O'Donovan , SV Parikh , G MacQueen , RS McIntyre , V Sharma , S Beaulieu (2006). Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disorder 8, 721739.

RC Young , JT Biggs , VE Ziegler , DA Meyer (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429435.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: